PCSA Relative Valuation
PCSA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PCSA is overvalued; if below, it's undervalued.
Historical Valuation
Processa Pharmaceuticals Inc (PCSA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.10. The fair price of Processa Pharmaceuticals Inc (PCSA) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：3.46
Fair
-0.47
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Processa Pharmaceuticals Inc. (PCSA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-0.03
EV/EBIT
Processa Pharmaceuticals Inc. (PCSA) has a current EV/EBIT of -0.03. The 5-year average EV/EBIT is -1.95. The thresholds are as follows: Strongly Undervalued below -8.60, Undervalued between -8.60 and -5.28, Fairly Valued between 1.37 and -5.28, Overvalued between 1.37 and 4.69, and Strongly Overvalued above 4.69. The current Forward EV/EBIT of -0.03 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Processa Pharmaceuticals Inc. (PCSA) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
Processa Pharmaceuticals Inc. (PCSA) has a current P/OCF of 0.00. The 5-year average P/OCF is -4.59. The thresholds are as follows: Strongly Undervalued below -31.97, Undervalued between -31.97 and -18.28, Fairly Valued between 9.10 and -18.28, Overvalued between 9.10 and 22.79, and Strongly Overvalued above 22.79. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Processa Pharmaceuticals Inc. (PCSA) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.82. The thresholds are as follows: Strongly Undervalued below -9.87, Undervalued between -9.87 and -5.85, Fairly Valued between 2.20 and -5.85, Overvalued between 2.20 and 6.22, and Strongly Overvalued above 6.22. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Processa Pharmaceuticals Inc (PCSA) has a current Price-to-Book (P/B) ratio of 1.06. Compared to its 3-year average P/B ratio of 1.14 , the current P/B ratio is approximately -6.78% higher. Relative to its 5-year average P/B ratio of 1.94, the current P/B ratio is about -45.21% higher. Processa Pharmaceuticals Inc (PCSA) has a Forward Free Cash Flow (FCF) yield of approximately -161.66%. Compared to its 3-year average FCF yield of -195.62%, the current FCF yield is approximately -17.36% lower. Relative to its 5-year average FCF yield of -122.27% , the current FCF yield is about 32.22% lower.
1.06
P/B
Median3y
1.14
Median5y
1.94
-161.66
FCF Yield
Median3y
-195.62
Median5y
-122.27
Competitors Valuation Multiple
The average P/S ratio for PCSA's competitors is 11.59, providing a benchmark for relative valuation. Processa Pharmaceuticals Inc Corp (PCSA) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PCSA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PCSA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is Processa Pharmaceuticals Inc (PCSA) currently overvalued or undervalued?
Processa Pharmaceuticals Inc (PCSA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.10. The fair price of Processa Pharmaceuticals Inc (PCSA) is between to according to relative valuation methord.
What is Processa Pharmaceuticals Inc (PCSA) fair value?
PCSA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Processa Pharmaceuticals Inc (PCSA) is between to according to relative valuation methord.
How does PCSA's valuation metrics compare to the industry average?
The average P/S ratio for PCSA's competitors is 11.59, providing a benchmark for relative valuation. Processa Pharmaceuticals Inc Corp (PCSA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Processa Pharmaceuticals Inc (PCSA) as of Jan 09 2026?
As of Jan 09 2026, Processa Pharmaceuticals Inc (PCSA) has a P/B ratio of 1.06. This indicates that the market values PCSA at 1.06 times its book value.
What is the current FCF Yield for Processa Pharmaceuticals Inc (PCSA) as of Jan 09 2026?
As of Jan 09 2026, Processa Pharmaceuticals Inc (PCSA) has a FCF Yield of -161.66%. This means that for every dollar of Processa Pharmaceuticals Inc’s market capitalization, the company generates -161.66 cents in free cash flow.
What is the current Forward P/E ratio for Processa Pharmaceuticals Inc (PCSA) as of Jan 09 2026?
As of Jan 09 2026, Processa Pharmaceuticals Inc (PCSA) has a Forward P/E ratio of -0.47. This means the market is willing to pay $-0.47 for every dollar of Processa Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Processa Pharmaceuticals Inc (PCSA) as of Jan 09 2026?
As of Jan 09 2026, Processa Pharmaceuticals Inc (PCSA) has a Forward P/S ratio of 0.00. This means the market is valuing PCSA at $0.00 for every dollar of expected revenue over the next 12 months.